147 related articles for article (PubMed ID: 947511)
1. Immune evaluation with skin testing. A study of testicular, prostatic, and bladder neoplasms.
Schellhammer PF; Bracken RB; Bean MA; Pinsky CM; Whitmore WF
Cancer; 1976 Jul; 38(1):149-56. PubMed ID: 947511
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of host immunocompetence in urologic cancer patients.
Catalona WJ; Smolev JK; Harty JI
J Urol; 1975 Dec; 114(6):922-6. PubMed ID: 1195475
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous response to dinitrochlorobenzene in patients with genito-urinary cancers.
Duclos H; Schwarzenberg L; Duclos SH; Hugues H; Kuss R
Biomedicine; 1977 Jan; 27(1):43-7. PubMed ID: 856314
[TBL] [Abstract][Full Text] [Related]
4. Skin testing in genitourinary carcinoma: 2-year followup.
Decenzo JM; Allison R; Leadbetter GW
J Urol; 1975 Aug; 114(2):271-3. PubMed ID: 1171996
[TBL] [Abstract][Full Text] [Related]
5. Immunological evaluation in patients with urological cancers.
Martinez-Piñeiro JA; Muntanola P; Hidalgo L
Eur Urol; 1977; 3(3):159-62. PubMed ID: 560302
[TBL] [Abstract][Full Text] [Related]
6. The value of the DNCB test in bladder cancer. Pretreatment evaluation of immune function and 5-year follow-up of patients with urinary bladder cancer.
Flamm J; Sagaster P; Micksche M
Urol Int; 1984; 39(5):257-63. PubMed ID: 6506358
[TBL] [Abstract][Full Text] [Related]
7. Serum ribonuclease in urologic cancer. Relation to host immunocompetence.
Catalona WJ; Chretien PB; Matthews WJ; Tarpley JL
Urology; 1973 Nov; 2(5):577-81. PubMed ID: 4797457
[No Abstract] [Full Text] [Related]
8. The effects of treatment on delayed cutaneous hypersensitivity responses (DNCB, croton oil, and recall antigen) in patients with genitourinary cancer.
Elhilali MM; Brosman SA; Vescera C; Paul JG; Fahey JL
Cancer; 1978 May; 41(5):1765-70. PubMed ID: 647626
[No Abstract] [Full Text] [Related]
9. Abnormalities of cell-mediated immunocompetence in genitourinary cancer.
Catalona WJ; Chretien PB; Trahan EE
J Urol; 1974 Feb; 111(2):229-32. PubMed ID: 4855735
[No Abstract] [Full Text] [Related]
10. The cancer associated antigen test as an index to failure of complete removal of urological cancers.
Wechsler M; Gerfo PL; Feminella J; Lattimer JK
J Urol; 1973 Apr; 109(4):699-701. PubMed ID: 4735168
[No Abstract] [Full Text] [Related]
11. [The prognostic significance of the immune status (DNCB-test) in patients with carcinoma of the bladder, checked by observation of the course of disease (author's transl)].
Flamm J; Burkert S
Wien Med Wochenschr; 1981; 131(13-14):339-43. PubMed ID: 7281701
[TBL] [Abstract][Full Text] [Related]
12. [Value of carcinoembryonic antigen (CEA) in the diagnosis of malignant tumors of the urogenital tract].
Rost A; Kneppenberg U; Rost P
Helv Chir Acta; 1976 Jul; 43(3):271-8. PubMed ID: 947865
[TBL] [Abstract][Full Text] [Related]
13. Preliminary report of an immunological study in urological cancer.
Serrallach N; Jimenez JF; Aguiló F; Anguera A; Clavo M; Orejas V; Torner V; Serrate R
Eur Urol; 1975; 1(2):99-100. PubMed ID: 1241896
[TBL] [Abstract][Full Text] [Related]
14. Carcinoembryonic antigen in patients with tumors of the urogenital tract.
Reynoso G; Chu TM; Guinan P; Murphy GP
Cancer; 1972 Jul; 30(1):1-4. PubMed ID: 5064805
[No Abstract] [Full Text] [Related]
15. Immunology of genitourinary tumors.
Guinan P; Sadoughi N; Bush IM; John T; Eghrari F; Ablin RJ
Urology; 1973 Nov; 2(5):493-9. PubMed ID: 4131868
[No Abstract] [Full Text] [Related]
16. The value of urinary neopterin as an immunological parameter in patients with malignant tumors of the genitourinary tract.
Frick J; Aulitzky W; Fuchs D; Hausen A; Joos H; Reibnegger G; Wachter H
Urol Int; 1985; 40(3):155-9. PubMed ID: 3874460
[TBL] [Abstract][Full Text] [Related]
17. Immunologic features of genitourinary cancer.
Javadpour N
Urology; 1973 Aug; 2(2):103-8. PubMed ID: 4129366
[No Abstract] [Full Text] [Related]
18. Correlations among cutaneous reactivity to DNCB, PHA-induced lymphocyte blastogenesis and peripheral blood E rosettes.
Catalona WJ; Tarpley JL; Potvin C; Chretien PB
Clin Exp Immunol; 1975 Feb; 19(2):327-33. PubMed ID: 1082390
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of serum tissue polypeptide antigen (TPA) in patients with urogenital cancer].
Tozuka K; Yonese Y; Nakagami Y; Minowa T; Hiraoka Y; Yamada N; Hikima N; Ishii Y; Tannowa K; Fujioka Y
Gan To Kagaku Ryoho; 1984 May; 11(5):1078-83. PubMed ID: 6721513
[TBL] [Abstract][Full Text] [Related]
20. The occurrence of SV40-Neutralizing antibodies in sera of patients with genitourinary carcinoma.
Shah KV; Palma LD; Murphy GP
J Surg Oncol; 1971; 3(4):443-50. PubMed ID: 4329010
[No Abstract] [Full Text] [Related]
[Next] [New Search]
